- Home
- CAG vs EXEL Comparison
CAG vs EXEL Comparison
Compare CAG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | EXEL |
|---|---|---|
| Founded | 1919 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CAG | EXEL |
|---|---|---|
| Price | $17.99 | $41.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 24 |
| Target Price | $20.67 | ★ $45.18 |
| AVG Volume (30 Days) | ★ 9.5M | 2.6M |
| Earning Date | 12-19-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.89% | N/A |
| EPS Growth | ★ 73.36 | 53.55 |
| EPS | 1.77 | ★ 2.38 |
| Revenue | ★ $11,450,500,000.00 | $2,288,218,000.00 |
| Revenue This Year | N/A | $9.84 |
| Revenue Next Year | N/A | $11.92 |
| P/E Ratio | ★ $10.03 | $17.20 |
| Revenue Growth | N/A | ★ 9.93 |
| 52 Week Low | $16.60 | $31.90 |
| 52 Week High | $28.52 | $49.62 |
Technical Indicators
Market Signals| Indicator | CAG | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.32 | 46.23 |
| Support Level | $16.86 | $40.66 |
| Resistance Level | $17.35 | $44.79 |
| Average True Range (ATR) | 0.32 | 1.15 |
| MACD | 0.09 | -0.43 |
| Stochastic Oscillator | 97.90 | 15.53 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.